Sun Pharma chairman calls Organon deal both happy and anxious moment

Sun Pharmaceutical Industries' Executive Chairman Dilip Shanghvi described the Organon acquisition as both exciting and worrying due to its size and debt burden. He expressed confidence in repayment and highlighted expansion into China and biosimilars as key strategic gains. The acquisition is a large transaction that Sun Pharma is entering into, with Organon valued at less than 25 per cent of Sun Pharma's valuation.